Japanese Encephalitis Vaccine (JE-Shield SD Vaccine)

Product Details

Packaging Size           : 0.5 ml in 1 prefilled syringe
Brand                           : JE-Shield SD Vaccine
Manufacturer            : Abbott
Composition              : Inactivated Japanese Encephalitis virus protein (5mcg)
Treatment                   : protects against JE and is given as part of universal immunization program for selected places endem
Prescription/Non prescription Prescription
Form                            : Liquid
Shelf life                      : 24 Months
Storage                         : Cool & Dry place
Packaging type           : Box


JE-Shield SD Vaccine: Protecting Against Japanese Encephalitis

JE-Shield SD Vaccine is instrumental in safeguarding against Japanese Encephalitis Vaccine(JE), a potentially life-threatening disease. Administered as part of the universal immunization program in endemic areas, this vaccine is crucial for protecting individuals against JE.

Vaccination Guidelines

Healthcare providers assess eligibility for the JE-Shield SD Vaccine based on specific circumstances. Typically, children aged 1 to 3 years and adults aged 18 to 49 years are recommended to receive this subcutaneous injection.

Recommended Recipients

JE-Shield SD Vaccine is particularly recommended for individuals traveling to JE-endemic regions, especially for stays exceeding one month. Additionally, frequent travelers to such areas and those with increased risk factors should also consider vaccination to mitigate the threat of JE.

Understanding Japanese Encephalitis

While most Japanese Encephalitis Vaccine infections present with mild symptoms such as fever and headache, severe cases can lead to neurological complications, including paralysis and even death. Prompt vaccination is crucial in preventing the onset of severe clinical illness associated with JE.

Diagnostic Measures

For individuals living in or traveling to JE-endemic areas who exhibit symptoms of encephalitis, a laboratory test is crucial to confirm JEV infection. The World Health Organization (WHO) recommends testing for JEV-specific IgM antibodies in cerebrospinal fluid or serum samples using an IgM-capture ELISA.

Treatment and Management

Unfortunately, there is no specific antiviral treatment available for JE. Management of JE primarily involves supportive care to alleviate symptoms and stabilize the patient’s condition.


JE-Shield SD Vaccine stands as a vital defense against the threat of Japanese encephalitis. Adhering to vaccination guidelines and prioritizing preventive measures effectively combat the spread of JE, safeguarding public health. Furthermore, educating individuals about the importance of vaccination and promoting awareness initiatives can further enhance JE prevention efforts.

Read More


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.